{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:55:25Z","timestamp":1791467725777,"version":"4.3.4"},"update-to":[{"DOI":"10.1002\/14651858.cd015906","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000}}],"reference-count":213,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015906.pub2","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T11:25:46Z","timestamp":1763637946000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dipeptidyl peptidase 4 (DPP-4) inhibitors for people with chronic kidney disease and diabetes"],"prefix":"10.1002","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2825-2993","authenticated-orcid":false,"given":"Patrizia","family":"Natale","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"},{"name":"Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J); University of Bari Aldo Moro; Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suetonia C","family":"Green","sequence":"additional","affiliation":[{"name":"Department of Medicine; University of Otago Christchurch; Christchurch New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Tunnicliffe","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"},{"name":"Centre for Kidney Research; The Children's Hospital at Westmead; Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pellegrino","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J); University of Bari Aldo Moro; Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Toyama","sequence":"additional","affiliation":[{"name":"Department of Nephrology; Faculty of Medical Sciences, University of Fukui; Fukui Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[{"name":"Sydney School of Public Health; The University of Sydney; Sydney Australia"},{"name":"Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE-J); University of Bari Aldo Moro; Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"supported by Cochrane Kidney and Transplant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"10.1002\/14651858.CD015906.pub2-BIB0001|cit1","unstructured":"World Health Organization Diabetes Available from https:\/\/www.who.int\/health-topics\/diabetes#tab=tab_1"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"10085","key":"10.1002\/14651858.CD015906.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(17)30058-2","article-title":"Type 2 diabetes [Erratum in: Lancet. 2017 Jun 3;389(10085):2192]","volume":"389","author":"Chatterjee","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1002\/14651858.CD015906.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"e011295","DOI":"10.1161\/JAHA.118.011295","article-title":"Diabetes mellitus-related all-cause and cardiovascular mortality in a national cohort of adults","volume":"19","author":"Raghavan","year":"2019","journal-title":"Journal of the American Heart Association"},{"issue":"1","key":"10.1002\/14651858.CD015906.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12955-020-01311-5","article-title":"Health-related quality of life and associated factors among patients with diabetes mellitus at the University of Gondar referral hospital","volume":"18","author":"Aschalew","year":"2020","journal-title":"Health & Quality Life Outcomes"},{"issue":"1","key":"10.1002\/14651858.CD015906.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"e001258","DOI":"10.1136\/bmjgh-2018-001258","article-title":"The costs of diabetes treatment in low- and middle-income countries: a systematic review","volume":"4","author":"Moucheraud","year":"2019","journal-title":"BMJ Global Health"},{"issue":"10159","key":"10.1002\/14651858.CD015906.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [Erratum in: Lancet. 2019 Jun 22;393(10190):e44]","volume":"392","author":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators","year":"2018","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0008|cit8","unstructured":"McDonald S Excell L Dent H ANZDATA 32nd Annual Report. 2009 Report : Data to 2008. Chapter 2: New patients commencing treatment in 2008 Available from https:\/\/www.anzdata.org.au\/report\/anzdata-32nd-annual-report-2009\/"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s41100-018-0183-6","article-title":"Annual dialysis data report 2016, JSDT renal data registry","volume":"4","author":"Masakane","year":"2018","journal-title":"Renal Replacement Therapy"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0010|cit10","unstructured":"United States Renal Data System. 2018 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD Available from https:\/\/www.niddk.nih.gov\/about-niddk\/strategic-plans-reports\/usrds\/prior-data-reports\/2018"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0011|cit11","first-page":"S1","article-title":"Excerpts from the United States Renal Data System 2007 Annual Data Report","volume":"51","author":"Collins","year":"2008","journal-title":"American Journal of Kidney Diseases"},{"issue":"12","key":"10.1002\/14651858.CD015906.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.4065\/83.12.1373","article-title":"Rationale and strategies for early detection and management of diabetic kidney disease","volume":"83","author":"Radbill","year":"2008","journal-title":"Mayo Clinic Proceedings"},{"issue":"7","key":"10.1002\/14651858.CD015906.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s40265-015-0385-y","article-title":"Alogliptin: a review of its use in patients with type 2 diabetes mellitus","volume":"75","author":"Keating","year":"2015","journal-title":"Drugs"},{"issue":"2","key":"10.1002\/14651858.CD015906.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.diabres.2010.07.006","article-title":"DPP-4 inhibitors: what may be the clinical differentiators?","volume":"90","author":"Gerich","year":"2010","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"15","key":"10.1002\/14651858.CD015906.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2018.3024","article-title":"Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"319","author":"Zheng","year":"2018","journal-title":"JAMA"},{"issue":"5","key":"10.1002\/14651858.CD015906.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00125-016-3899-2","article-title":"Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism","volume":"59","author":"Ahr\u00e9n","year":"2016","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"i2231","DOI":"10.1136\/bmj.i2231","article-title":"Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis","volume":"353","author":"Salvo","year":"2016","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0018|cit18","doi-asserted-by":"crossref","unstructured":"KDIGO Working Group KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease Available from https:\/\/kdigo.org\/wp-content\/uploads\/2022\/10\/KDIGO-2022-Clinical-Practice-Guideline-for-Diabetes-Management-in-CKD.pdf","DOI":"10.22141\/2307-1257.10.4.2021.247896"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0019|cit19","unstructured":"Pharmacokinetics in patients with impaired renal function\u2014study design, data analysis, and impact on dosing. Guidance for industry (March 2024) Available from https:\/\/www.fda.gov\/media\/78573\/download"},{"issue":"3","key":"10.1002\/14651858.CD015906.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes [Erratum in: N Engl J Med. 2015 Aug 6;373(6):586]","volume":"373","author":"Green","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015906.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"14","key":"10.1002\/14651858.CD015906.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"10.1002\/14651858.CD015906.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD015906.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1042\/CS20180031","article-title":"The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin [Erratum in: Clin Sci (Lond). 2019 Jan 15;133(1):151]","volume":"132","author":"Kanasaki","year":"2018","journal-title":"Clinical Science"},{"issue":"3","key":"10.1002\/14651858.CD015906.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1177\/2042098614523031","article-title":"Safety of dipeptidyl peptidase 4 inhibitors: a perspective review","volume":"5","author":"Karagiannis","year":"2014","journal-title":"Therapeutic Advances in Drug Safety"},{"issue":"1","key":"10.1002\/14651858.CD015906.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40360-020-00447-w","article-title":"Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system","volume":"21","author":"Huang","year":"2020","journal-title":"BMC Pharmacology & Toxicology"},{"issue":"1","key":"10.1002\/14651858.CD015906.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ecl.2017.10.006","article-title":"Managing diabetes and cardiovascular risk in chronic kidney disease patients","volume":"47","author":"Lovre","year":"2018","journal-title":"Endocrinology & Metabolism Clinics of North America"},{"issue":"9","key":"10.1002\/14651858.CD015906.pub2-BIB0028|cit28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011798.pub2","article-title":"Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease","author":"Lo","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD015906.pub2-BIB0029|cit29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015849.pub2","article-title":"Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes","author":"Natale","year":"2025","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD015906.pub2-BIB0030|cit30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015907","article-title":"Thiazolidinediones for people with chronic kidney disease and diabetes","author":"Natale","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD015906.pub2-BIB0031|cit31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015588.pub2","article-title":"Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes","author":"Natale","year":"2024","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD015906.pub2-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.73","article-title":"Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Levin","year":"2012","journal-title":"Kidney International Supplements"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0033|cit33","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological Expectations of Cochrane Intervention Reviews . Cochrane: London, Version August 2023 Available from https:\/\/community.cochrane.org\/mecir-manual"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD015906.pub2-BIB0035|cit35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015906","article-title":"Dipeptidyl peptidase 4 (DPP-4) inhibitors for people with chronic kidney disease and diabetes","author":"Natale","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0036|cit36","unstructured":"The SONG Handbook Version 1.0. 2017 Available from https:\/\/songinitiative.org\/reports-and-publications\/"},{"issue":"1","key":"10.1002\/14651858.CD015906.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"e000700","DOI":"10.1136\/bmjdrc-2019-000700","article-title":"Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 diabetes (SCORE-IT): a patient and healthcare professional consensus on a core outcome set for type 2 diabetes","volume":"7","author":"Harman","year":"2019","journal-title":"BMJ Open Diabetes Research & Care"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0038|cit38","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 (archived) Available from https:\/\/training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0039|cit39","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0041|cit41","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial (chapter last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0042|cit42","unstructured":"Higgins JP Eldridge S Chapter 23: Including variants on randomized trials (chapter last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0043|cit43","unstructured":"Eldridge S Campbell M Campbell M Dahota A Giraudeau B Higgins J Revised Cochrane risk of bias tool for randomized trials (RoB 2.0). Additional considerations for cluster-randomized trials Available from https:\/\/www.riskofbias.info\/welcome\/rob-2-0-tool\/archive-rob-2-0-cluster-randomized-trials-2016 (accessed 31 October 2025)"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0044|cit44","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing evidence in a meta-analysis (chapter last updated August 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from www.training.cochrane.org\/handbook"},{"issue":"7414","key":"10.1002\/14651858.CD015906.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0046|cit46","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence (chapter last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.training.cochrane.org\/handbook"},{"issue":"7650","key":"10.1002\/14651858.CD015906.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD015906.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0049|cit49","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2025"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0050|cit50","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions (last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/www.training.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD015906.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12933-020-01046-z","article-title":"Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and\/or insulin: a randomized controlled trial","volume":"19","author":"Awal","year":"2020","journal-title":"Cardiovascular Diabetology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0052|cit52","first-page":"A218","article-title":"Role of linagliptin on CD34+ endothelial progenitor cells and arterial stiffness in renal function impaired type 2 diabetes subjects [abstract no: SUN-578]","volume":"4","author":"Awal","year":"2020","journal-title":"Journal of the Endocrine Society"},{"issue":"3","key":"10.1002\/14651858.CD015906.pub2-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2337\/dc22-1699","article-title":"Optimization of albuminuria-lowering treatment in diabetes by crossover rotation to four different drug classes: a randomized crossover trial","volume":"46","author":"Curovic","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1681\/ASN.20233411S1856b","article-title":"Overall and interindividual effect of four different drug classes on soluble urokinase plasminogen activator receptor in albuminuric type 1 and type 2 diabetes [abstract no: SA-PO478]","volume":"34","author":"Curovic","year":"2023","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2337\/db22-21-OR","article-title":"Optimization of albuminuria lowering treatment by crossover rotation to four different drug classes","volume":"71","author":"Curovic","year":"2022","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0056|cit56","doi-asserted-by":"publisher","first-page":"S388","DOI":"10.1007\/s00125-022-05755-w","article-title":"Optimisation of albuminuria lowering treatment by cross-over rotation to four different drug classes [abstract no: 752]","volume":"65","author":"Rotbain Curovic","year":"2022","journal-title":"Diabetologia"},{"issue":"11","key":"10.1002\/14651858.CD015906.pub2-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1111\/dom.15209","article-title":"Overall and inter-individual effect of four different drug classes on soluble urokinase plasminogen activator receptor in type 1 and type 2 diabetes","volume":"25","author":"Rotbain Curovic","year":"2023","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"9","key":"10.1002\/14651858.CD015906.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2337\/dc08-1984","article-title":"The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone","volume":"32","author":"DeFronzo","year":"2009","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD015906.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2213-8587(13)70084-6","article-title":"Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"1","author":"Roden","year":"2013","journal-title":"Lancet Diabetes & Endocrinology"},{"issue":"7","key":"10.1002\/14651858.CD015906.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.2337\/dc16-0303","article-title":"Cardiovascular mortality in patients with type 2 diabetes and recent acute coronary syndromes from the EXAMINE trial","volume":"39","author":"White","year":"2016","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1002\/14651858.CD015906.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.ahj.2011.08.004","article-title":"EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome","volume":"162","author":"White","year":"2011","journal-title":"American Heart Journal"},{"issue":"14","key":"10.1002\/14651858.CD015906.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"9982","key":"10.1002\/14651858.CD015906.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet"},{"issue":"20","key":"10.1002\/14651858.CD015906.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1161\/CIRCULATIONAHA.116.024632","article-title":"Serial measurement of high-sensitivity troponin I and cardiovascular outcomes in patients with type 2 diabetes mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care)","volume":"135","author":"Cavender","year":"2017","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"35","DOI":"10.4103\/jrms.JRMS_78_20","article-title":"Effect of sitagliptin on proteinuria in patients with type 2 diabetes - a renoprotective effect of sitagliptin","volume":"26","author":"Narimani","year":"2021","journal-title":"Journal of Research in Medical Sciences"},{"issue":"4","key":"10.1002\/14651858.CD015906.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"696","DOI":"10.2337\/dc14-1850","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial","volume":"38","author":"Udell","year":"2015","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1002\/14651858.CD015906.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.2337\/dc15-0006","article-title":"Comment on Udell et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care 2015;38:696-705","volume":"38","author":"Kalra","year":"2015","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1002\/14651858.CD015906.pub2-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/s1957-2557%2813%2970594-7","article-title":"Study on the risk reduction of cardiovascular events with saxagliptin in type 2 diabetic patients (SAVOR-TIMI 53): Study and patients description","volume":"7","author":"Krempf","year":"2013","journal-title":"Medecine des Maladies Metaboliques"},{"issue":"2","key":"10.1002\/14651858.CD015906.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/dom.12582","article-title":"Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial","volume":"18","author":"Leiter","year":"2016","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD015906.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/dmrr.2413","article-title":"Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial","volume":"29","author":"Mosenzon","year":"2013","journal-title":"Diabetes\/Metabolism Research Reviews"},{"issue":"11","key":"10.1002\/14651858.CD015906.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.2337\/dc15-1068","article-title":"Incidence of fractures in patients with type 2 diabetes in the SAVOR-TIMI 53 trial","volume":"38","author":"Mosenzon","year":"2015","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1002\/14651858.CD015906.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.ahj.2011.08.006","article-title":"The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study","volume":"162","author":"Scirica","year":"2011","journal-title":"American Heart Journal"},{"issue":"18","key":"10.1002\/14651858.CD015906.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","article-title":"Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial","volume":"130","author":"Scirica","year":"2014","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD015906.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/jamacardio.2017.4228","article-title":"Cardiovascular outcomes according to urinary albumin and kidney disease in patients with type 2 diabetes at high cardiovascular risk: observations from the SAVOR-TIMI 53 trial","volume":"3","author":"Scirica","year":"2018","journal-title":"JAMA Cardiology"},{"issue":"22 Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0075|cit75","article-title":"Outcomes of patients with type 2 diabetes and known congestive heart failure treated with saxagliptin: Analyses of the SAVOR-TIMI 53 study [abstract]","volume":"128","author":"Scirica","year":"2013","journal-title":"Circulation"},{"issue":"14","key":"10.1002\/14651858.CD015906.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"S355","DOI":"10.1007\/s00125-017-4350-z","article-title":"Clinically significant change in albumin creatinine ratio with saxagliptin: a post hoc analysis from the SAVOR-TIMI 53 trial [abstract no: 755]","volume":"60","author":"Mosenzon","year":"2017","journal-title":"Diabetologia"},{"issue":"4","key":"10.1002\/14651858.CD015906.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1161\/CIRCULATIONAHA.119.044819","article-title":"Response by Bergmark et al to letter regarding article, \"Metformin use and clinical outcomes among patients with diabetes mellitus with or without heart failure or kidney dysfunction: observations from the SAVOR-TIMI 53 trial\"","volume":"141","author":"Bergmark","year":"2020","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD015906.pub2-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1161\/CIRCULATIONAHA.119.043268","article-title":"Letter by Mordi et al regarding article, \"metformin use and clinical outcomes among patients with diabetes mellitus with or without heart failure or kidney dysfunction: observations from the SAVOR-TIMI 53 trial\"","volume":"141","author":"Mordi","year":"2020","journal-title":"Circulation"},{"issue":"12","key":"10.1002\/14651858.CD015906.pub2-BIB0080|cit80","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1161\/CIRCULATIONAHA.119.040144","article-title":"Metformin use and clinical outcomes among patients with diabetes mellitus with or without heart failure or kidney dysfunction: observations from the SAVOR-TIMI 53 trial","volume":"140","author":"Bergmark","year":"2019","journal-title":"Circulation"},{"issue":"8","key":"10.1002\/14651858.CD015906.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2337\/dc15-2763","article-title":"Predisposing factors for any and major hypoglycemia with saxagliptin versus placebo and overall: analysis from the SAVOR-TIMI 53 trial","volume":"39","author":"Cahn","year":"2016","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD015906.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2337\/dc16-0621","article-title":"Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial","volume":"40","author":"Mosenzon","year":"2017","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1002\/14651858.CD015906.pub2-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"5906-11","DOI":"10.52711\/0974-360X.2023.00957","article-title":"Effect of Teneligliptin in comparison with Voglibose as an add on therapy in reducing microvascular complications in type II diabetes mellitus patients - a prospective randomized control trial","volume":"16","author":"Sivasankari","year":"2023","journal-title":"Research Journal of Pharmacy & Technology"},{"issue":"11","key":"10.1002\/14651858.CD015906.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/dom.12983","article-title":"Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS","volume":"19","author":"Engel","year":"2017","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD015906.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"494","DOI":"10.2337\/dc16-1135","article-title":"Assessing the safety of sitagliptin in older participants in the trial evaluating cardiovascular outcomes with sitagliptin (TECOS)","volume":"40","author":"Bethel","year":"2017","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1002\/14651858.CD015906.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2337\/dc15-2780","article-title":"Pancreatic safety of sitagliptin in the TECOS study","volume":"40","author":"Buse","year":"2017","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1002\/14651858.CD015906.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.ahj.2013.09.003","article-title":"Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease","volume":"166","author":"Green","year":"2013","journal-title":"American Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD015906.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/jamacardio.2016.0103","article-title":"Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial","volume":"1","author":"McGuire","year":"2016","journal-title":"JAMA Cardiology"},{"issue":"13","key":"10.1002\/14651858.CD015906.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1161\/CIRCULATIONAHA.117.027252","article-title":"Secondary prevention of cardiovascular disease in patients with type 2 diabetes mellitus: international insights from the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin)","volume":"136","author":"Pagidipati","year":"2017","journal-title":"Circulation"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"S361","DOI":"10.1007\/s00125-016-4046-9","article-title":"Assessing the safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) [abstract no: 759]","volume":"59","author":"Engel","year":"2016","journal-title":"Diabetologia"},{"issue":"12","key":"10.1002\/14651858.CD015906.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.2337\/dc16-1415","article-title":"Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: outcomes from TECOS","volume":"39","author":"Cornel","year":"2017","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD015906.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. [Erratum appears in N Engl J Med. 2015 Aug 6;373(6):586; PMID: 26182233]","volume":"373","author":"Green","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD015906.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/dc17-1778","article-title":"Risk of severe hypoglycemic events before and after cardiovascular outcomes in TECOS suggests an at-risk type 2 diabetes frail patient phenotype","volume":"41","author":"Standl","year":"2018","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1002\/14651858.CD015906.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.2337\/dc12-2718","article-title":"Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a \u226552-week randomized, double-blind study","volume":"36","author":"Yki-J\u00e4rvinen","year":"2013","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD015906.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1185\/03007995.2015.1010638","article-title":"Linagliptin improves glycemic control after 1 year as add-on therapy to basal insulin in Asian patients with type 2 diabetes mellitus","volume":"31","author":"Sheu","year":"2015","journal-title":"Current Medical Research & Opinion"},{"issue":"2","key":"10.1002\/14651858.CD015906.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1210\/jc.2015-3716","article-title":"Acute effects of linagliptin on progenitor cells, monocyte phenotypes, and soluble mediators in type 2 diabetes","volume":"101","author":"Fadini","year":"2016","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD015906.pub2-BIB0097|cit97","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s13340-016-0258-y","article-title":"Efficacy of linagliptin and teneligliptin for glycemic control in type 2 diabetic patients with chronic kidney disease: assessment by continuous glucose monitoring; a pilot study","volume":"7","author":"Tanaka","year":"2016","journal-title":"Diabetology International"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/jdi.12012","article-title":"Linagliptin lowers albuminuria on top of recommended standard treatment for diabetic nephropathy [abstract no: OCS-07-2]","volume":"3","author":"Groop","year":"2012","journal-title":"Journal of Diabetes Investigation"},{"issue":"11","key":"10.1002\/14651858.CD015906.pub2-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.2337\/dc13-0323","article-title":"Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction","volume":"36","author":"Groop","year":"2013","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1007\/s00125-012-2688-9","article-title":"Effects of the DPP-4 inhibitor linagliptin on albuminuria in patients with type 2 diabetes and diabetic nephropathy [abstract no: 36]","volume":"55","author":"Groop","year":"2012","journal-title":"Diabetologia"},{"issue":"6","key":"10.1002\/14651858.CD015906.pub2-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/dom.12281","article-title":"Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment","volume":"16","author":"Groop","year":"2014","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"6","key":"10.1002\/14651858.CD015906.pub2-BIB0102|cit102","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1111\/dom.13258","article-title":"Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on versus sequential add-on to metformin and of triple versus dual therapy with metformin","volume":"20","author":"Del Prato","year":"2018","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"85-91","DOI":"10.1142\/S2575900024500058","article-title":"Comparison of the efficacy of dapagliflozin and linagliptin in the treatment of type 2 diabetes patients with normal body mass index and poor metformin monotherapy","volume":"7","author":"Mingli","year":"2024","journal-title":"Traditional Medicine & Modern Medicine"},{"issue":"2","key":"10.1002\/14651858.CD015906.pub2-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jcjd.2021.07.004","article-title":"A new clinical utility for tubular markers to identify kidney responders to saxagliptin treatment in adults with diabetic nephropathy","volume":"46","author":"Mohsen","year":"2022","journal-title":"Canadian Journal of Diabetes"},{"issue":"6","key":"10.1002\/14651858.CD015906.pub2-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/dom.13988","article-title":"Effect of adding vildagliptin to insulin in haemodialysed patients with type 2 diabetes: the VILDDIAL study, a randomized, multicentre, prospective study","volume":"22","author":"Munch","year":"2020","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"i317","DOI":"10.1093\/ndt\/gfy104.SaO007","article-title":"Effect of adding vildagliptin to insulin therapy in type 2 diabetic dialysis patients: the VILDDIAL study - a randomized multicentric prospective study [abstract no: SaO007]","volume":"33","author":"Chantrel","year":"2018","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0107|cit107","first-page":"A242","article-title":"Randomized, multicentric, prospective study assessing the effect of adding vildagliptin to insulin in hemodialysed type 2 diabetic patients-the VILDDIALl study [abstract]","volume":"67","author":"Munch","year":"2018","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"S510","DOI":"10.1007\/s00125-018-4693-0","article-title":"Effect of vildagliptin added to insulin on glycaemic control in haemodialysis patients with type 2 diabetes: a randomised multicentre prospective study [abstract no: 1042]","volume":"61","author":"Smagala","year":"2018","journal-title":"Diabetologia"},{"issue":"12","key":"10.1002\/14651858.CD015906.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s00125-016-4083-4","article-title":"Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial","volume":"59","author":"Ott","year":"2016","journal-title":"Diabetologia"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD015906.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"iii11","DOI":"10.1093\/ndt\/gfv139.03","article-title":"Effects of linagliptin on early alterations of renal endothelial function in patients with type-2 diabetes [abstract]","volume":"30","author":"Schmieder","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD015906.pub2-BIB0111|cit111","first-page":"1657-63","article-title":"Efficacy of dapagliflozin versus sitagliptin on type 2 diabetes mellitus","volume":"13","author":"Donepudi","year":"2023","journal-title":"European Journal of Cardiovascular Medicine"},{"issue":"3","key":"10.1002\/14651858.CD015906.pub2-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"183-9","DOI":"10.47583\/ijpsrr.2024.v84i03.025","article-title":"Efficacy and safety of empagliflozin versus linagliptin as add on therapy to insulin in patients of chronic kidney disease and type 2 diabetes mellitus: a randomised controlled trial","volume":"84","author":"Hameed","year":"2024","journal-title":"International Journal of Pharmaceutical Sciences Review & Research"},{"issue":"1","key":"10.1002\/14651858.CD015906.pub2-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1038\/s41598-023-30643-7","article-title":"The effect of linagliptin on microalbuminuria in patients with diabetic nephropathy: a randomized, double blinded clinical trial","volume":"13","author":"Karimifar","year":"2023","journal-title":"Scientific Reports"},{"issue":"5","key":"10.1002\/14651858.CD015906.pub2-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"344","DOI":"10.52547\/ijkd.6110","article-title":"The renoprotective effect of linagliptin in type 2 diabetic patients with severely increased albuminuria","volume":"15","author":"Moeinzadeh","year":"2021","journal-title":"Iranian Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD015906.pub2-BIB0115|cit115","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40842-022-00142-1","article-title":"Comparison of effects of Empagliflozin and Linagliptin on renal function and glycaemic control: a double-blind, randomized clinical trial","volume":"8","author":"Mohammad Zadeh Gharabaghi","year":"2022","journal-title":"Clinical Diabetes & Endocrinology"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0116|cit116","first-page":"S360","article-title":"Sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes and advanced chronic kidney disease [abstract no: 758]","volume":"59","author":"Bellante","year":"2016","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.diabres.2016.04.034","article-title":"Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: a randomized open-label prospective trial","volume":"116","author":"Abe","year":"2016","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"i216","DOI":"10.1093\/ndt\/gfw169.01","article-title":"Efficacy and safety of dipeptidyl peptidase-4 (DPP-4) inhibitor in hemodialysis patients with type 2 diabetes [abstract no: SP379]","volume":"31","author":"Abe","year":"2016","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD015906.pub2-BIB0119|cit119","first-page":"65","article-title":"Efficacy and safety of saxagliptin, dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with type 2 diabetes [abstract]","volume":"21","author":"Abe","year":"2016","journal-title":"Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD015906.pub2-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"e13007","DOI":"10.1111\/eci.13007","article-title":"Liraglutide relieves cardiac dilated function than DPP-4 inhibitors","volume":"48","author":"Hiramatsu","year":"2018","journal-title":"European Journal of Clinical Investigation"},{"issue":"11","key":"10.1002\/14651858.CD015906.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1507\/endocrj.EJ11-0025","article-title":"The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis","volume":"58","author":"Ito","year":"2011","journal-title":"Endocrine Journal"},{"issue":"2","key":"10.1002\/14651858.CD015906.pub2-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/jdi.13126","article-title":"Efficacy and safety of trelagliptin in Japanese patients with type 2 diabetes with severe renal impairment or end-stage renal disease: results from a randomized, phase 3 study","volume":"11","author":"Kaku","year":"2020","journal-title":"Journal of Diabetes Investigation"},{"issue":"3","key":"10.1002\/14651858.CD015906.pub2-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/jdi.12142","article-title":"Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus","volume":"5","author":"Mori","year":"2014","journal-title":"Journal of Diabetes Investigation"},{"issue":"1","key":"10.1002\/14651858.CD015906.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"e000265","DOI":"10.1136\/bmjdrc-2016-000265","article-title":"Linagliptin monotherapy compared with voglibose monotherapy in patients with type 2 diabetes undergoing hemodialysis: a 12-week randomized trial","volume":"4","author":"Mori","year":"2016","journal-title":"BMJ Open Diabetes Research & Care"},{"issue":"12","key":"10.1002\/14651858.CD015906.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"893","DOI":"10.5551\/jat.18333","article-title":"Rationale, design, and baseline characteristics of a trial for the prevention of diabetic atherosclerosis using a DPP-4 inhibitor: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A)","volume":"20","author":"Katakami","year":"2013","journal-title":"Journal of Atherosclerosis & Thrombosis"},{"issue":"3","key":"10.1002\/14651858.CD015906.pub2-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s13300-020-00991-y","article-title":"Effects of the once-weekly DPP4 inhibitor omarigliptin on glycemic control in patients with type 2 diabetes mellitus on maintenance hemodialysis: a 24-week open-label, multicenter randomized controlled study","volume":"12","author":"Yoshizawa","year":"2021","journal-title":"Diabetes Therapy Research, Treatment & Education of Diabetes & Related Disorders"},{"issue":"4","key":"10.1002\/14651858.CD015906.pub2-BIB0127|cit127","first-page":"498-502","article-title":"Comparing the effect of the SGLT-2 Inhibitors and DPP-4 Inhibitor combined therapy with sulphonylureas and metformin combined therapy in patients with type 2 diabetic nephropathy","volume":"14","author":"Ali","year":"2023","journal-title":"Journal of Pharmaceutical Negative Results"},{"issue":"4","key":"10.1002\/14651858.CD015906.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/dom.12863","article-title":"Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study)","volume":"19","author":"Yoon","year":"2017","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0129|cit129","first-page":"S387","article-title":"Efficacy and safety of gemigliptin in type 2 diabetes patients with moderate to severe renal impairment [abstract no: 804]","volume":"58","author":"Yoon","year":"2015","journal-title":"Diabetologia"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0130|cit130","first-page":"S361","article-title":"Efficacy and safety of gemigliptin in type 2 diabetes patients with moderate to severe renal impairment (GUARD study) [abstract no: 760]","volume":"59","author":"Yoon","year":"2016","journal-title":"Diabetologia"},{"issue":"2","key":"10.1002\/14651858.CD015906.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/dom.13059","article-title":"Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: a 40-week extension of the GUARD randomized study","volume":"20","author":"Han","year":"2018","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0132|cit132","doi-asserted-by":"publisher","first-page":"110872","DOI":"10.1016\/j.diabres.2023.110872","article-title":"Comparison of therapeutic efficacy and safety of sitagliptin, dapagliflozin, or lobeglitazone adjunct therapy in patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea and metformin: third agent study","volume":"203","author":"Hong","year":"2023","journal-title":"Diabetes Research & Clinical Practice"},{"issue":"3","key":"10.1002\/14651858.CD015906.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"328-37","DOI":"10.3803\/EnM.2023.1688","article-title":"Efficacy of gemigliptin add-on to dapagliflozin and metformin in type 2 diabetes patients: a randomized, double-blind, placebo-controlled study (SOLUTION)","volume":"38","author":"Lee","year":"2023","journal-title":"Endocrinology & Metabolism"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0134|cit134","doi-asserted-by":"publisher","first-page":"7382620","DOI":"10.1155\/2021\/7382620","article-title":"Effect of dipeptidyl peptidase-4 (DPP-4) inhibition on biomarkers of kidney injury and vascular calcification in diabetic kidney disease: a randomized controlled trial","volume":"2021","author":"Trakarnvanich","year":"2021","journal-title":"Journal of Diabetes Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0135|cit135","doi-asserted-by":"publisher","first-page":"i66","DOI":"10.1093\/ndt\/gfab149.004","article-title":"Effect of gemigliptin on biomarkers of kidney injury and vascular calcification in diabetic nephropathy: a randomized controlled trial [abstract no: FC 092]","volume":"36","author":"Trakarnvanich","year":"2021","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD015906.pub2-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.nefro.2020.04.023","article-title":"The effect of linagliptin on renal progression in type-2 diabetes mellitus patients with chronic kidney disease: a prospective randomized controlled study","volume":"40","author":"Yagoglu","year":"2020","journal-title":"Nefrologia"},{"issue":"17","key":"10.1002\/14651858.CD015906.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1517\/14656566.2012.740459","article-title":"Black\/African American patients with type 2 diabetes mellitus: study design and baseline patient characteristics from a randomized clinical trial of linagliptin","volume":"13","author":"Thrasher","year":"2012","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"4","key":"10.1002\/14651858.CD015906.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1053\/j.ajkd.2012.11.043","article-title":"Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial","volume":"61","author":"Arjona Ferreira","year":"2013","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD015906.pub2-BIB0139|cit139","first-page":"430","article-title":"Efficacy and safety of sitagliptin vs. glipizide in patients with type 2 diabetes mellitus and end-stage renal disease on dialysis: A 54-week randomised trial [abstract]","volume":"20","author":"Arjona Ferreira","year":"2011","journal-title":"Diabetes, Stoffwechsel und Herz"},{"issue":"Abstracts","key":"10.1002\/14651858.CD015906.pub2-BIB0140|cit140","first-page":"8B","article-title":"Efficacy and safety of sitagliptin vs. glipizide in patients with type 2 diabetes and end-stage renal disease on dialysis [abstract no: LB-PO3167]","volume":"22","author":"Arjona Ferreira","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9902","key":"10.1002\/14651858.CD015906.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(13)61500-7","article-title":"Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Barnett","year":"2013","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0142|cit142","first-page":"102","article-title":"Efficacy and safety of linagliptin in elderly patients (\u2265 70 years) with type 2 diabetes mellitus [abstract no: OCS-05-3]","volume":"3","author":"Barnett","year":"2012","journal-title":"Journal of Diabetes Investigation"},{"issue":"1","key":"10.1002\/14651858.CD015906.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/1479164113507068","article-title":"Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment","volume":"11","author":"McGill","year":"2014","journal-title":"Diabetes & Vascular Disease Research"},{"issue":"1","key":"10.1002\/14651858.CD015906.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0145|cit145","first-page":"S357","article-title":"CARMELINA trial baseline characteristics: a cardiovascular and renal microvascular outcome trial with linagliptin in patients with type 2 diabetes at high vascular risk [abstract no: 779]","volume":"60","author":"Perkovic","year":"2017","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0146|cit146","first-page":"A344","article-title":"CARMELINA trial baseline characteristics: a cardiovascular and renal microvascular outcome trial with linagliptin in patients with type 2 diabetes at high vascular risk [abstract]","volume":"66","author":"Rosenstock","year":"2017","journal-title":"Diabetes"},{"issue":"1","key":"10.1002\/14651858.CD015906.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12933-018-0682-3","article-title":"Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA: a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk","volume":"17","author":"Rosenstock","year":"2018","journal-title":"Cardiovascular Diabetology"},{"issue":"9","key":"10.1002\/14651858.CD015906.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1093\/ckj\/sfab104","article-title":"Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (T2D): the CARMELINA randomised controlled trial","volume":"14","author":"Wanner","year":"2021","journal-title":"Clinical Kidney Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0149|cit149","doi-asserted-by":"publisher","first-page":"SUN","DOI":"10.1210\/js.2019-SUN-LB015","article-title":"Baseline characteristics and effects on CV and kidney outcomes with linagliptin versus placebo, across GFR categories in CARMELINA [abstract no: SUN-LB015]","volume":"3","author":"Kahn","year":"2019","journal-title":"Journal of the Endocrine Society"},{"issue":"10","key":"10.1002\/14651858.CD015906.pub2-BIB0150|cit150","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.2337\/dc19-0783","article-title":"Effect of linagliptin on cognitive performance in patients with type 2 diabetes and cardiorenal comorbidities: the CARMELINA randomized trial","volume":"42","author":"Biessels","year":"2019","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0151|cit151","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1007\/s00125-019-4946-6","article-title":"Relationship between hypoglycaemia, cardiovascular (CV) outcomes and all-cause mortality (ACM) in type 2 diabetes (T2D) in the CARMELINA trial [abstract no: 125]","volume":"62","author":"Rosenstock","year":"2019","journal-title":"Diabetologia"},{"issue":"4","key":"10.1002\/14651858.CD015906.pub2-BIB0152|cit152","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1080\/00325481.2020.1742524","article-title":"Linagliptin in patients with type 2 diabetes and cardiovascular and\/or renal disease: results from a cardiovascular and renal outcomes trial","volume":"132","author":"Guthrie","year":"2020","journal-title":"Postgraduate Medicine"},{"issue":"2","key":"10.1002\/14651858.CD015906.pub2-BIB0153|cit153","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s13340-019-00412-x","article-title":"Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and\/or kidney disease: subgroup analysis of the randomized CARMELINA trial","volume":"11","author":"Inagaki","year":"2020","journal-title":"Diabetology International"},{"issue":"3","key":"10.1002\/14651858.CD015906.pub2-BIB0154|cit154","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1161\/CIRCULATIONAHA.118.038352","article-title":"Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA","volume":"139","author":"McGuire","year":"2019","journal-title":"Circulation"},{"issue":"8","key":"10.1002\/14651858.CD015906.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.2337\/dc20-0279","article-title":"Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: secondary analysis of the CARMELINA randomized trial","volume":"43","author":"Perkovic","year":"2020","journal-title":"Diabetes Care"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD015906.pub2-BIB0156|cit156","first-page":"B1","article-title":"Effect of linagliptin on kidney and cardiovascular outcomes in patients with type 2 diabetes and kidney disease: CARMELINA [abstract no: FR-OR142]","volume":"29","author":"Perkovic","year":"2018","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD015906.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"226\u201336","DOI":"10.1093\/ckj\/sfaa225","article-title":"Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial","volume":"14","author":"Wanner","year":"2021","journal-title":"Clinical Kidney Journal"},{"issue":"7","key":"10.1002\/14651858.CD015906.pub2-BIB0158|cit158","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/dom.13995","article-title":"Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and\/or kidney disease: a prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA trial","volume":"22","author":"Cooper","year":"2020","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"9","key":"10.1002\/14651858.CD015906.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/j.1742-1241.2009.02143.x","article-title":"Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. [Erratum appears in Int J Clin Pract. 2010 Jan;64(2):277]","volume":"63","author":"Chacra","year":"2009","journal-title":"International Journal of Clinical Practice"},{"issue":"6","key":"10.1002\/14651858.CD015906.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ijcp.12955","article-title":"A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment","volume":"71","author":"Chacra","year":"2017","journal-title":"International Journal of Clinical Practice"},{"issue":"7","key":"10.1002\/14651858.CD015906.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1463-1326.2008.00914.x","article-title":"Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency","volume":"10","author":"Chan","year":"2008","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"12","key":"10.1002\/14651858.CD015906.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1111\/dom.13473","article-title":"A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: the CompoSIT-R study","volume":"20","author":"Scott","year":"2018","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0163|cit163","doi-asserted-by":"publisher","first-page":"S379-80","DOI":"10.1007\/s00125-018-4693-0","article-title":"Safety and efficacy of sitagliptin compared with dapagliflozin in patients with type 2 diabetes, mild renal impairment, and inadequate glycaemic control on metformin \u00b1 a sulfonylurea [abstract no: 744]","volume":"61","author":"Raji","year":"2018","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0164|cit164","first-page":"A306","article-title":"Safety and efficacy of sitagliptin (SITA) compared with dapagliflozin (DAPA) in subjects with T2D, mild renal impairment, and inadequate glycemic control on metformin (MET) +\/- a sulfonylurea (SU) [abstract]","volume":"67","author":"Scott","year":"2018","journal-title":"Diabetes"},{"issue":"10","key":"10.1002\/14651858.CD015906.pub2-BIB0165|cit165","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1007\/s13300-020-00907-w","article-title":"Efficacy and safety of sitagliptin compared with dapagliflozin in people >= 65 years old with type 2 diabetes and mild renal insufficiency","volume":"11","author":"Raji","year":"2020","journal-title":"Diabetes Therapy Research, Treatment & Education of Diabetes & Related Disorders"},{"issue":"12","key":"10.1002\/14651858.CD015906.pub2-BIB0166|cit166","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1056\/NEJMoa2200436","article-title":"Glycemia reduction in type 2 diabetes - microvascular and cardiovascular outcomes","volume":"387","author":"Nathan","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD015906.pub2-BIB0167|cit167","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1001\/jamainternmed.2023.1487","article-title":"Comparative effects of glucose-lowering medications on kidney outcomes in type 2 diabetes: the GRADE randomized clinical trial","volume":"183","author":"Wexler","year":"2023","journal-title":"JAMA Internal Medicine"},{"issue":"12","key":"10.1002\/14651858.CD015906.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1210\/jc.2009-0550","article-title":"Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone","volume":"94","author":"Hollander","year":"2009","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"9","key":"10.1002\/14651858.CD015906.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1007\/s00125-015-3655-z","article-title":"Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial","volume":"58","author":"Kothny","year":"2015","journal-title":"Diabetologia"},{"issue":"2","key":"10.1002\/14651858.CD015906.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.2337\/dc14-1684","article-title":"Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial","volume":"38","author":"Laakso","year":"2015","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0171|cit171","doi-asserted-by":"publisher","first-page":"S364","DOI":"10.1007\/s00125-013-3012-z","article-title":"Linagliptin versus placebo followed by glimepiride in type 2 diabetes patients with moderate to severe renal impairment [abstract no: P13-11527]","volume":"56","author":"Groop","year":"2016","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0172|cit172","first-page":"A281","article-title":"Linagliptin vs. placebo followed by glimepiride in type 2 diabetes patients with moderate to severe renal impairment [abstract no: 1090-P]","volume":"62","author":"Laakso","year":"2013","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0173|cit173","first-page":"A264","article-title":"Long-term efficacy and safety of linagliptin in type 2 diabetes patients with moderate to severe renal disease [abstract no: 1025-P]","volume":"63","author":"Groop","year":"2014","journal-title":"Diabetes"},{"issue":"10","key":"10.1002\/14651858.CD015906.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.2337\/dc13-2855","article-title":"Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study","volume":"37","author":"Leiter","year":"2014","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0175|cit175","first-page":"S361","article-title":"HARMONY 8: once-weekly glucagon-like peptide 1 receptor agonist albiglutide vs sitagliptin for patients with type 2 diabetes with renal impairment: week 26 results [abstract no: 906]","volume":"56","author":"Leiter","year":"2013","journal-title":"Diabetologia"},{"issue":"9","key":"10.1002\/14651858.CD015906.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.clinthera.2012.07.008","article-title":"Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial","volume":"34","author":"Lewin","year":"2012","journal-title":"Clinical Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD015906.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/1479164113507068","article-title":"Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment","volume":"11","author":"McGill","year":"2014","journal-title":"Diabetes & Vascular Disease Research"},{"issue":"10","key":"10.1002\/14651858.CD015906.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1463-1326.2011.01467.x","article-title":"Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial","volume":"13","author":"Lukashevich","year":"2011","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"11","key":"10.1002\/14651858.CD015906.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/j.1463-1326.2012.01634.x","article-title":"One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment","volume":"14","author":"Kothny","year":"2012","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0180|cit180","first-page":"A253","article-title":"One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes mellitus and moderate or severe renal insufficiency [abstract no: 992-P]","volume":"61","author":"Kothny","year":"2012","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0181|cit181","first-page":"S332","article-title":"Efficacy of vildagliptin therapy in combination with insulin in patients with type 2 diabetes and severe renal impairment [abstract no: 820]","volume":"54","author":"Lukashevich","year":"2011","journal-title":"Diabetologia"},{"issue":"2","key":"10.1002\/14651858.CD015906.pub2-BIB0182|cit182","first-page":"257","article-title":"Experience with vildagliptin in patients >=75 years with type 2 diabetes and moderate or severe renal impairment","volume":"4","author":"Schweizer","year":"2013","journal-title":"Diabetes Therapy Research, Treatment & Education of Diabetes & Related Disorders"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0183|cit183","doi-asserted-by":"publisher","first-page":"S332","DOI":"10.1007\/s00125-011-2276-4","article-title":"Comparison of vildagliptin with placebo in a 24-week study of 221 patients with type 2 diabetes and severe renal impairment (eGFR<30) [abstract no: 819]","volume":"54","author":"Kothny","year":"2011","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/VHRM.S39300","article-title":"Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment","volume":"9","author":"Lukashevich","year":"2013","journal-title":"Vascular Health & Risk Management"},{"issue":"11","key":"10.1002\/14651858.CD015906.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/dom.13041","article-title":"Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial","volume":"19","author":"Groop","year":"2017","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"6","key":"10.1002\/14651858.CD015906.pub2-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/1479164115579002","article-title":"Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: rationale and design of the MARLINA-T2DTM trial","volume":"12","author":"Groop","year":"2015","journal-title":"Diabetes & Vascular Disease Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"i35","DOI":"10.1093\/ndt\/gfy104.FO041","article-title":"Urinary proteomics may unmask the renal potential of the DPP-4 inhibitor linagliptin in patients with diabetic kidney disease [abstract no: FO041]","volume":"33","author":"Siwy","year":"2018","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0188|cit188","doi-asserted-by":"publisher","first-page":"S360","DOI":"10.1007\/s00125-016-4046-9","article-title":"Effects of linagliptin on glycaemic control and albuminuria in type 2 diabetes: the MARLINA-T2DTM trial [abstract no: 757]","volume":"59","author":"Schernthaner","year":"2016","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"i35","DOI":"10.1093\/ndt\/gfy104.FO041","article-title":"Urinary proteomics may unmask the renal potential of the DPP-4 inhibitor linagliptin in patients with diabetic kidney disease [abstract no: FO041]","volume":"33","author":"Siwy","year":"2018","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD015906.pub2-BIB0190|cit190","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1097\/HJH.0000000000002032","article-title":"Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin-angiotensin system inhibitors in type 2 diabetic patients with albuminuria","volume":"37","author":"Cooper","year":"2019","journal-title":"Journal of Hypertension"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD015906.pub2-BIB0191|cit191","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/nep.12887","article-title":"Effects of linagliptin on glycaemic control and albuminuria in type 2 diabetes-the MARLINA-T2DTM trial [abstract]","volume":"21","author":"Schernthaner","year":"2016","journal-title":"Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD015906.pub2-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"e1800144","DOI":"10.1002\/prca.201800144","article-title":"Urinary proteomics as a tool to identify kidney responders to dipeptidyl peptidase-4 inhibition: a hypothesis-generating analysis from the MARLINA-T2D trial","volume":"13","author":"Siwy","year":"2019","journal-title":"Proteomics Clinical Applications"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0193|cit193","first-page":"544A","article-title":"Linagliptin and changes in novel urinary biomarker panels in type 2 diabetes: a predefined substudy from the MARLINA-T2D trial [abstract no: FR-PO811]","volume":"27","author":"Tseng","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD015906.pub2-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2337\/dc12-0706","article-title":"Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: A 1-year, randomized, double-blind, placebo-controlled study","volume":"36","author":"McGill","year":"2013","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1002\/14651858.CD015906.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/1479164113507068","article-title":"Linagliptin added to sulphonylurea in uncontrolled type 2 diabetes patients with moderate-to-severe renal impairment","volume":"11","author":"McGill","year":"2014","journal-title":"Diabetes & Vascular Disease Research"},{"issue":"4","key":"10.1002\/14651858.CD015906.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/1479164115579001","article-title":"Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease","volume":"12","author":"McGill","year":"2015","journal-title":"Diabetes & Vascular Disease Research"},{"issue":"6","key":"10.1002\/14651858.CD015906.pub2-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1463-1326.2011.01382.x","article-title":"Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment","volume":"13","author":"Nowicki","year":"2011","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"12","key":"10.1002\/14651858.CD015906.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1742-1241.2011.02812.x","article-title":"Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study","volume":"65","author":"Nowicki","year":"2011","journal-title":"International Journal of Clinical Practice"},{"issue":"1","key":"10.1002\/14651858.CD015906.pub2-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1758-5996-4-36","article-title":"The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial","volume":"4","author":"Frederich","year":"2012","journal-title":"Diabetology & Metabolic Syndrome"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD015906.pub2-BIB0200|cit200","doi-asserted-by":"publisher","first-page":"iii615","DOI":"10.1093\/ndt\/gfx175","article-title":"Paricalcitol and dipeptidyl pepetidase 4 (DPP4) inhibitors the effect on resistin in type 2 diabetic and renal disease patients [abstract no: MP508]","volume":"32","author":"Mendes","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015906.pub2-BIB0201|cit201","doi-asserted-by":"publisher","first-page":"A147","DOI":"10.1089\/dia.2019.2525.abstracts","article-title":"DPP-4 inhibitors (linagliptin) impact on klotho serum level in patients with type 2 diabetes [abstract no: 330]","volume":"21","author":"Milovanova","year":"2019","journal-title":"Diabetes Technology & Therapeutics"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0202|cit202","unstructured":"A randomized controlled study of proline hengaricin tablets for the treatment of type 2 diabetes mellitus and prevention of early progression of diabetic kidney disease https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2400087971 2024"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0203|cit203","unstructured":"Study of therapeutic effect of sitagliptin https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=IRCT20200420047147N2 2022"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0204|cit204","unstructured":"Comparison the effects of empaglifluzin-linagliptin and dapaglifluzin-linagliptin on HbA1c? LDL and albuminuria in patients with T2DM https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=IRCT20221221056889N1 2023"},{"key":"10.1002\/14651858.CD015906.pub2-BIB0205|cit205","unstructured":"A phase 4, monocenter, randomized, double-blind, comparator-controlled, 3-armed parallel mechanistic intervention trial to assess the effect of 8-week empagliflozin (SGLT-2 inhibitor) monotherapy, followed by 8-week empagliflozin and linagliptin (DPP-4 inhibitor) combination therapy versus 8-week linagliptin monotherapy, followed by 8-week linagliptin and empagliflozin combination therapy versus 8-week gliclazide (Sulfonylurea derivate), followed by 8-week gliclazide intensification therapy on r - Renal Actions of Combined Empagliflozin and LINagliptin in type 2 diabetES https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=NL-OMON48622 2019"},{"issue":"4","key":"10.1002\/14651858.CD015906.pub2-BIB0206|cit206","doi-asserted-by":"publisher","first-page":"283","DOI":"10.4103\/ijem.ijem_237_21","article-title":"Effects of DPP4 inhibitors on renal outcomes in diabetes mellitus: a systematic review and meta-analysis","volume":"25","author":"Dalui","year":"2021","journal-title":"Indian Journal of Endocrinology & Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD015906.pub2-BIB0207|cit207","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s13300-016-0189-4","article-title":"Systematic literature review of DPP-4 inhibitors in patients with type 2 diabetes mellitus and renal impairment","volume":"7","author":"Thomas","year":"2016","journal-title":"Diabetes Therapy"},{"issue":"2","key":"10.1002\/14651858.CD015906.pub2-BIB0208|cit208","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000454683","article-title":"Dipeptidyl peptidase-4 inhibitors in chronic kidney disease: a systematic review of randomized clinical trials","volume":"136","author":"Walker","year":"2017","journal-title":"Nephron"},{"issue":"10","key":"10.1002\/14651858.CD015906.pub2-BIB0209|cit209","doi-asserted-by":"publisher","first-page":"e111543","DOI":"10.1371\/journal.pone.0111543","article-title":"Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysis","volume":"9","author":"Cheng","year":"2014","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"3","key":"10.1002\/14651858.CD015906.pub2-BIB0210|cit210","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/jdi.13675","article-title":"Dipeptidyl peptidase-4 inhibitor and insulin combination treatment in type 2 diabetes and chronic kidney disease: a meta-analysis","volume":"13","author":"Zhou","year":"2022","journal-title":"Journal of Diabetes Investigation"},{"issue":"2","key":"10.1002\/14651858.CD015906.pub2-BIB0211|cit211","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3803\/EnM.2020.912","article-title":"Comparative renal effects of dipeptidyl peptidase-4 inhibitors and sodium-glucose cotransporter 2 inhibitors on individual outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"36","author":"Bae","year":"2021","journal-title":"Endocrinology & Metabolism"},{"issue":"6","key":"10.1002\/14651858.CD015906.pub2-BIB0212|cit212","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.clinthera.2012.04.013","article-title":"Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review [Erratum in: Clin Ther. 2014 Feb 1;36(2):307-8]","volume":"34","author":"Aroda","year":"2012","journal-title":"Clinical Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD015906.pub2-BIB0213|cit213","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.diabres.2015.05.025","article-title":"The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"109","author":"Mishriky","year":"2015","journal-title":"Diabetes Research & Clinical Practice"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:02:59Z","timestamp":1791464579000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015906.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":213,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015906.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]}}}